Harvard’s New Melanoma Vaccine Tech Enters Ph I Trial

By Zachary Brennan

- Last updated on GMT

New Melanoma Vaccine Tech Enters Ph I Trial
New Melanoma Vaccine Tech Enters Ph I Trial

Related tags Immune system Vaccine Cancer

A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.

The technology, developed by the Wyss Institute for Biologically Inspired Engineering at Harvard University, uses 8.5 millimetre disk-like sponges made from US FDA-approved polymers.

The disks, which release cytokines, recruit dendritic cells that enter the implants’ pores where they are exposed to antigens specific to the type of tumor being targeted. The dendritic cells then report to nearby lymph nodes, where they direct the immune system's T-cells to kill tumor cells, according to the preclinical study results from 2009 published in Science Translational Medicine​.

In simpler terms, the sponge implanted under the skin is designed to recruit and reprogram a patient's immune cells, and then instructs them to travel through the body and kill the cancer cells.

Dr. David Mooney, PhD, professor of bioengineering at Harvard, told BioPharma-Reporter.com, “The polymer [that makes up the disks] is poly(lactide-co-glycolide) - the same polymer used to fabricate biodegradable sutures​.” He added that “the process we use [to manufacture the sponges] is a high pressure, carbon dioxide foaming technique​.”

The vaccine technology is unlike what’s used in most therapeutic cancer vaccines available today, such as Denderon’s prostate cancer vaccine Provenge, where doctors must initially remove the patient's immune cells, then reprogram them and reintroduce them back into the patient. More than 90 percent of reinjected cells from vaccines currently available die before having any impact, according to Harvard.

Early Progress

The success of the preclinical study, which found 50 percent of mice treated with two doses of the vaccine showed complete tumor regression, means the vaccine was able to enter human trials earlier.

"It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly​," said Dr. Glenn Dranoff, professor of medicine at Harvard Medical School.

Dr. Mooney added that the Phase I trial began three to four years “after we first published on the technology, which is considered quite fast​.”

The use of the vaccine technology also may not be just limited to fighting melanoma.

This is potentially useful for a range of solid tumors​,” Dr. Mooney said. “But this trial will only examine its utility in melanoma​.”

Related news

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us